Skip to main content
. 2022 Aug 19;2(9):100169. doi: 10.1016/j.xgen.2022.100169

Figure 2.

Figure 2

Patient voices reveal the landscape of living with metastatic prostate cancer

(A–D) Self-reported data of 706 patient partners related to their prostate cancer.

(A) Patient partners were asked for the current location of their cancer. Participants were free to choose multiple if their cancer had metastasized to multiple locations.

(B–D) Responses were tabulated from questions asking patient partners if their initial prostate cancer diagnosis was metastatic (B), if they have a family history of prostate/breast cancer (C), or if they have ever had another cancer diagnosis (D). Patient partners who did not complete these questions (n < 5 for all questions) are not shown.

(E) Self-reported therapies show strong overlap with medical records. Therapy categories are shown on the y axis, with the proportion of patient partners from each data type (patient surveys and medical records) receiving therapies of that category shown on the x axis. In the online survey, patient partners selected therapies they received for their metastatic prostate cancer from a list. 639/706 patient partners reported at least one therapy and are shown. 119 of these participants also had abstracted therapy data from medical records. Report overlap refers to how often patient partners report receiving a therapy when their medical records show that they have received that therapy as a percentage. Only therapies available for selection in the patient survey were used in this comparison (Table S4).

(F) Landscape of lifestyle changes for patient partners. Participants were asked to list additional medications, alternative medications, or lifestyle changes since their diagnosis of prostate cancer. Free-text responses were manually abstracted and categorized into diet/lifestyle changes, supplements, and non-cancer medications. The y axis shows individual instances of diet/lifestyle changes, supplements, or medications. The x axis shows the percentage of patient partners with that lifestyle change or that were taking that supplement/therapy out of all patient partners that responded to the lifestyle question (n = 456). CBD/THC, cannabidiol/tetrahydrocannabinol (oils, medical marijuana, etc.).